Condition
Esophagogastric Junction Adenocarcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Esophagogastric Junction Adenocarcinoma clinical trials that are recruiting, at sites in 2 countries (most in China (4), Germany (1)). By phase: Phase 2 (4), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Esophagogastric Junction Adenocarcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Tislelizumab plus FLOT given before surgery for operable esophagus or stomach adenocarcinoma | Phase 1 | Frankfurt and 3 other locations | Recruiting | Jul 10, 2025 |
| Combining Sintilimab with Chemotherapy for Stage III Gastric Cancer Treatment | Phase 2 | Beijing, Beijing Municipality | Recruiting | Jan 7, 2025 |
| Combining immunotherapy with chemotherapy for esophagogastric junction cancer treatment | Phase 2 | Shanghai, Shanghai Municipality | Recruiting | Jul 1, 2024 |
| Combining anti-PD-1 therapy with thymalfasin and chemotherapy for advanced gastric cancer treatment | Phase 2 | Nanjing, Jiangsu | Recruiting | Jun 17, 2024 |
| Neoadjuvant immunochemotherapy for advanced esophagogastric junction cancer | Phase 2 | Guangzhou, Guangdong | Recruiting | Dec 28, 2021 |
All recruiting trials (5)
-
Tislelizumab plus FLOT given before surgery for operable esophagus or stomach adenocarcinoma
This trial tests whether adding the immunotherapy drug tislelizumab to FLOT chemotherapy given before surgery helps people with locally advanced, resectable esophagus or stomach adenocarcinoma shrink tumors and better tolerate treatment.
-
Combining Sintilimab with Chemotherapy for Stage III Gastric Cancer Treatment
This study is testing if combining a new drug called Sintilimab with chemotherapy can help people with stage III gastric cancer feel better after their surgery.
-
Combining immunotherapy with chemotherapy for esophagogastric junction cancer treatment
This study is testing if combining a new immunotherapy drug with standard chemotherapy can help people with operable esophagogastric junction cancer feel better and improve their treatment outcomes.
-
Combining anti-PD-1 therapy with thymalfasin and chemotherapy for advanced gastric cancer treatment
This study is testing a new combination of treatments for people with advanced stomach cancer to see if it helps shrink tumors before surgery.
-
Neoadjuvant immunochemotherapy for advanced esophagogastric junction cancer
This study is testing a new combination of immunotherapy and chemotherapy to see if it helps patients with advanced esophagogastric junction cancer before they have surgery.
Related topics
Quick answers
How many Esophagogastric Junction Adenocarcinoma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (4 trials), Germany (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 4, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.